Clinical pharmacology in drug development · 2026-01
A healthy-adult crossover study assessed food, acid suppression and CYP3A interactions with oral tinlarebant. Food and omeprazole had limited exposure effects, while CYP3A inhibition or induction changed exposure. This is interaction evidence, not retinal efficacy evidence.
Program relevance
Tinlarebant pharmacokinetics in healthy adults, not the DRAGON Stargardt efficacy trial.
Formulation / population: Oral tinlarebant in healthy-adult drug-interaction and food-effect studies.
Healthy volunteers; no Stargardt efficacy outcome.
Protein assays, crystallography and mouse experiments examined how tinlarebant binds RBP4 and disrupts its association with transthyretin. The study describes a mechanism for lowering circulating RBP4; it is preclinical evidence.
Program relevance
Mechanistic experiments directly test tinlarebant, but do not report human Stargardt outcomes.
Formulation / population: Tinlarebant studied in purified-protein assays and mice.
Protein and animal experiments; not a clinical efficacy trial.